Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.

about

Can voluntary pooled procurement reduce the price of antiretroviral drugs? a case study of Efavirenz.

Item

http://www.wikidata.org/entity/Q39040089

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@en

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@nl

type

Item

label

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@en

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@nl

prefLabel

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@en

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@nl

P1476

Can voluntary pooled procureme ...... gs? a case study of Efavirenz.

@en

P2093

Jolene Skordis-Worrall

http://www.w3.org/2001/XMLSchema#string

Sung Wook Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Trends in procurement costs for HIV commodities: a 7-year retrospective analysis of global fund data across 125 countries.

Regional and temporal trends in malaria commodity costs: an analysis of Global Fund data for 79 countries.

Factors influencing global antiretroviral procurement prices.

Drug procurement, the Global Fund and misguided competition policies.

Enhancing medicine price transparency through price information mechanisms.

Intervening in global markets to improve access to HIV/AIDS treatment: an analysis of international policies and the dynamics of global antiretroviral medicines markets.

Pharmaceutical pricing in emerging markets: effects of income, competition, and procurement.

Exploring the influence of the Global Fund and the GAVI Alliance on health systems in conflict-affected countries.

A win-win solution?: A critical analysis of tiered pricing to improve access to medicines in developing countries

The make or buy debate: considering the limitations of domestic production in Tanzania.

P304

516-526

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/HEAPOL/CZW165

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-01-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28052986

http://www.w3.org/2001/XMLSchema#string